Guidance: Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosage
FDA issued final guidance on study design, data analysis, and dosage impact for pharmacokinetics in patients with impaired hepatic function, affecting drug development and labeling.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 1, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing (503B) facilities developing drugs with hepatic impairment considerations. should confirm how it applies to their specific situation before acting. There is a time constraint attached: No specific deadline stated; guidance is effective immediately upon publication.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The FDA finalized recommendations for designing and analyzing pharmacokinetic studies in patients with hepatic impairment and for assessing the impact on dosing recommendations.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing (503B) facilities developing drugs with hepatic impairment considerations.
What you must do
Review the guidance and update any ongoing or planned hepatic impairment studies and labeling to align with the recommendations.
Deadline
No specific deadline stated; guidance is effective immediately upon publication.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- What to Know About the FDA’s Recent Decision to Allow Florida to Import Prescription Drugs from Canada - kff.org
- Determination That NAMENDA (Memantine Hydrochloride) Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- FDA Warns Exosome Maker for Marketing Outside Its IND - medpagetoday.com
- FDA Proposes CGMP Framework for Animal Drug Compounding - Lab Manager
- GLP‑1 Compliance- FDA Targets Telehealth Marketing in 30 New Warning Letters - natlawreview.com